TP53 and uveal melanoma: For example, no in vitro synergy was observed for a combination of a protein kinase C inhibitor and a p53-MDM2 inhibitor in various uveal melanoma cell lines, whereas strong in vivo efficacy of the combination was observed in patient-derived xenografts relative to each compound given alone, probably due to p53-MDM2-induced apoptosis [7].